|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mohammed N, Kestin LL, Grills IS, Battu M,
Fitch DL, Wong CY, Margolis JH, Chmielewski GW and Welsh RJ: Rapid
disease progression with delay in treatment of non-small-cell lung
cancer. Int J Radiat Oncol Biol Phys. 79:466–472. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sato M, Shames DS, Gazdar AF and Minna JD:
A translational view of the molecular pathogenesis of lung cancer.
J Thorac Oncol. 2:327–343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu MX, Zhou KC and Cao Y: MCRS1
overexpression, which is specifically inhibited by miR-129*promotes
the epithelial-mesenchymal transition and metastasis in non-small
cell lung cancer. Mol Cancer. 13:2452014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu KL, Tsai MJ, Yang CJ, Chang WA, Hung
JY, Yen CJ, Shen CH, Kuo TY, Lee JY, Chou SH, et al: Liver
metastasis predicts poorer prognosis in stage IV lung
adenocarcinoma patients receiving first-line gefitinib. Lung
Cancer. 88:187–194. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pecina-Slaus N, Cicvara-Pecina T and Kafka
A: Epithelial-to-mesenchymal transition: Possible role in
meningiomas. Front Biosci (Elite Ed). 4:889–896. 2012.PubMed/NCBI
|
|
8
|
Guarino M, Rubino B and Ballabio G: The
role of epithelial-mesenchymal transition in cancer pathology.
Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hur K, Toiyama Y, Takahashi M, Balaguer F,
Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR and Goel A:
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT)
in human colorectal cancer metastasis. Gut. 62:1315–1326. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: an alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moustakas A and Heldin CH: Signaling
networks guiding epithelial-mesenchymal transitions during
embryogenesis and cancer progression. Cancer Sci. 98:1512–1520.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu Y, Sato F, Yamada T, Bhawal UK,
Kawamoto T, Fujimoto K, Noshiro M, Seino H, Morohashi S, Hakamada
K, et al: The BHLH transcription factor DEC1 plays an important
role in the epithelial-mesenchymal transition of pancreatic cancer.
Int J Oncol. 41:1337–1134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miyazono K, Suzuki H and Imamura T:
Regulation of TGF-beta signaling and its roles in progression of
tumors. Cancer Sci. 94:230–234. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nagaraj NS and Datta PK: Targeting the
transforming growth factor-beta signaling pathway in human cancer.
Expert Opin Investig Drugs. 19:77–91. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lv XQ, Qiao XR, Su L and Chen SZ: Honokiol
inhibits EMT-mediated motility and migration of human non-small
cell lung cancer cells in vitro by targeting c-FLIP. Acta Pharmacol
Sin. 37:1574–1586. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu J, Lamouille S and Derynck R:
TGF-beta-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Comijn J, Berx G, Vermassen P, Verschueren
K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D and van Roy
F: The two-handed E box binding zinc finger protein SIP1
downregulates E-cadherin and induces invasion. Mol Cell.
7:1267–1278. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pasquinelli AE: MicroRNAs and their
targets: Recognition, regulation and an emerging reciprocal
relationship. Nat Rev Genet. 13:271–282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Macfarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ha TY: MicroRNAs in human diseases: From
cancer to cardiovascular disease. Immune Netw. 11:135–154. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Arora A, Singh S, Bhatt AN, Pandey S,
Sandhir R and Dwarakanath BS: Interplay between metabolism and
oncogenic process: Role of microRNAs. Transl Oncogenomics. 7:11–27.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thompson BJ and Cohen SM: The Hippo
pathway regulates the bantam microRNA to control cell proliferation
and apoptosis in Drosophila. Cell. 126:767–774. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li M, Marin-Muller C, Bharadwaj U, Chow
KH, Yao Q and Chen C: MicroRNAs: Control and loss of control in
human physiology and disease. World J Surg. 33:667–684. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin PY, Yu SL and Yang PC: MicroRNA in
lung cancer. Br J Cancer. 103:1144–1148. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eis PS, Tam W, Sun L, Chadburn A, Li Z,
Gomez MF, Lund E and Dahlberg JE: Accumulation of miR-155 and BIC
RNA in human B cell lymphomas. Proc Natl Acad Sci USA.
102:3627–3632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kong W, He L, Coppola M, Guo J, Esposito
NN, Coppola D and Cheng JQ: MicroRNA-155 regulates cell survival,
growth and chemosensitivity by targeting FOXO3a in breast cancer. J
Biol Chem. 285:17869–17879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen J, Wang BC and Tang JH: Clinical
significance of microRNA-155 expression in human breast cancer. J
Surg Oncol. 106:260–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xie K, Ma H, Liang C, Wang C, Qin N, Shen
W, Gu Y, Yan C, Zhang K, Dai N, et al: A functional variant in
miR-155 regulation region contributes to lung cancer risk and
survival. Oncotarget. 6:42781–42792. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
O'Connell RM, Taganov KD, Boldin MP, Cheng
G and Baltimore D: MicroRNA-155 is induced during the macrophage
inflammatory response. Proc Natl Acad Sci USA. 104:1604–1609. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheng TL, Hu CP, Li M, Gu QH and An J:
Role of miR-155 in invasion and metastasis of lung adenocarcinoma
A549 cells. Zhonghua Zhong Liu Za Zhi. 38:86–92. 2016.(In Chinese).
PubMed/NCBI
|
|
34
|
Ji H, Tian D, Zhang B, Zhang Y, Yan D and
Wu S: Overexpression of miR-155 in clear-cell renal cell carcinoma
and its oncogenic effect through targeting FOXO3a. Exp Ther Med.
13:2286–2292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fu X, Wen H, Jing L, Yang Y, Wang W, Liang
X, Nan K, Yao Y and Tian T: MicroRNA-155-5p promotes hepatocellular
carcinoma progression by suppressing PTEN through the PI3K/Akt
pathway. Cancer Sci. 108:620–631. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gasparini P, Cascione L, Fassan M, Lovat
F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL and
Huebner K: microRNA expression profiling identifies a four microRNA
signature as a novel diagnostic and prognostic biomarker in triple
negative breast cancers. Oncotarget. 5:1174–1184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xiang X, Zhuang X, Ju S, Zhang S, Jiang H,
Mu J, Zhang L, Miller D, Grizzle W and Zhang HG: miR-155 promotes
macroscopic tumor formation yet inhibits tumor dissemination from
mammary fat pads to the lung by preventing EMT. Oncogene.
30:3440–3453. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Thomsen KG, Terp MG, Lund RR, Søkilde R,
Elias D, Bak M, Litman T, Beck HC, Lyng MB and Ditzel HJ: miR-155,
identified as anti-metastatic by global miRNA profiling of a
metastasis model, inhibits cancer cell extravasation and
colonization in vivo and causes significant signaling alterations.
Oncotarget. 6:29224–29239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen W, Huang L, Hao C, Zeng W, Luo X, Li
X, Zhou L, Jiang S, Chen Z and He Y: MicroRNA-155 promotes
apoptosis in SKOV3, A2780, and primary cultured ovarian cancer
cells. Tumour Biol. 37:9289–9299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Louafi F, Martinez-Nunez RT and
Sanchez-Elsner T: MicroRNA-155 targets SMAD2 and modulates the
response of macrophages to transforming growth factor-{beta}. J
Biol Chem. 285:41328–41336. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li CL, Nie H, Wang M, Su LP, Li JF, Yu YY,
Yan M, Qu QL, Zhu ZG and Liu BY: microRNA-155 is downregulated in
gastric cancer cells and involved in cell metastasis. Oncol Rep.
27:1960–1966. 2012.PubMed/NCBI
|
|
42
|
Liu WJ, Zhao YP, Zhang TP, Zhou L, Cui QC,
Zhou WX, You L, Chen G and Shu H: MLH1 as a direct target of
miR-155 and a potential predictor of favorable prognosis in
pancreatic cancer. J Gastrointest Surg. 17:1399–1405. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang Y, Li J, Tong L, Zhang J, Zhai A, Xu
K, Wei L and Chu M: The prognostic value of miR-21 and miR-155 in
non-small-cell lung cancer: A meta-analysis. Jpn J Clin Oncol.
43:813–820. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xu TP, Zhu CH, Zhang J, Xia R, Wu FL, Han
L, Shen H, Liu LX and Shu YQ: MicroRNA-155 expression has
prognostic value in patients with non-small cell lung cancer and
digestive system carcinomas. Asian Pac J Cancer Prev. 14:7085–7090.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
O'Connell RM, Kahn D, Gibson WS, Round JL,
Scholz RL, Chaudhuri AA, Kahn ME, Rao DS and Baltimore D:
MicroRNA-155 promotes autoimmune inflammation by enhancing
inflammatory T cell development. Immunity. 33:607–619. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Urbich C, Kuehbacher A and Dimmeler S:
Role of microRNAs in vascular diseases, inflammation, and
angiogenesis. Cardiovasc Res. 79:581–588. 2008. View Article : Google Scholar : PubMed/NCBI
|
